Virus-associated lymphomas

Current Opinion in Oncology

Volumn 11, Issue 5, 1999, Pages 322-332

  Cesarman, Ethel ^a,b   Mesri, Enrique A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELL GROWTH; CELL SURVIVAL; EPSTEIN BARR VIRUS; GENE EXPRESSION; HODGKIN DISEASE; HUMAN; HUMAN HERPESVIRUS 8; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNE RESPONSE; KAPOSI SARCOMA; LATENT PERIOD; LYMPHOMA; MOLECULAR GENETICS; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; REVIEW; VIRUS CARCINOGENESIS; VIRUS INFECTION;

GAMMAHERPESVIRINAE; HERPESVIRUS 4, HUMAN; HERPESVIRUS 8, HUMAN; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; LYMPHOMA;

EID: 0032873895     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199909000-00002     Document Type: Review

References (124)

1. Ellerman V, Bang O: Experimentelle Leukamie bei Huhnern. Zentalbl Bakteriol Alet I 1908, 46:595-597.
2. Rickinson AB, Kieff E: Epstein-Barr virus. In Virology, vol. 2. Edited by Fields BN, Knipe DM, Howley PM. Philadelphia:Lippincott-Raven; 1996:2397-2446.
3. Kieff E: Epstein-Barr virus and its replication. In Virology, vol. 2. Edited by Fields BN, Knipe DM, Howley PM. Philadelphia: Lippincott-Raven; 1996:2343-2396
4. Wilson JB, Bell JL, Levine A: Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. Embo J 1996, 15:3117-3126.
5. Grossman SR, Johannsen E, Tong X, Yalamanchili R, Kieff E. The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein. Proc Natl Acad Sci USA 1994, 91:7568-7572.
6. Hsieh JJ, Hayward SD: Masking of the CBF1/RBPJ kappa transcriptional repression domain by Epstein-Barr virus EBNA2. Science 1995, 268:560-563.
7. Wang D, Liebowitz D, Kieff E: An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985, 43:831-840.
8. Kulwichit W, Edwards RH, Davenport EM, Baskar JF, Godfrey V, Raab-Traub N: Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci U S A 1998, 95:11963-11968. Demonstration that LMP-1 can cause lymphomas in transgenic mice.
9. Kieser A, Kilger E, Gires O, Ueffing M, Kolch W, Hammerschmidt W: Epstein-Barr-virus latent membrane protein-1 triggers ap-1 activity via the c-jun n-terminal kinase cascade. Embo Journal 1997, 16:6478-6485.
10. Kilger E, Kieser A, Baumann M, Hammerschmidt W: Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. Embo Journal 1998, 17:1700-1709. Elegant molecular approach to demonstrate that LMP-1 constitutive activation of CD40-like signaling cascades is essential for B-cell transformation.
11. Eliopoulos AG, Blake SM, Floettmann JE, Rowe M, Young LS: Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. J Virol 1999, 73:1023-1035.
12. Dickens M, Rogers JS, Cavanagh J, Raitano A, Xia Z, Halpern JR, et al. A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 1997, 277:693-696.
13. Devergne O, McFarland EC, Mosialos G, Izumi KM, Ware CF, Kieff E: Role of the TRAF binding site and NF-kappaB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J Virol 1998, 72:7900-7908.
14. Yoshizaki T, Sato H, Furukawa M, Pagano JS: The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc Natl Acad Sci U S A 1998, 95:3621-3626.
15. Liebowitz D: Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 1998, 338:1413-1421. Demonstration of in vivo association of LMP1 with TRAF-1 and TRAF-3, and well as activation of NF-κB in lymphomas.
16. Chodosh J, Holder VP, Gan YJ, Belgaumi A, Sample J, Sixbey JW: Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype. J Infect Dis 1998, 177:1194-1201. Selective elimination of latent EBV by treatment with hydroxyurea, allowing comparison. May lead to methods for elimination of latent virus in vivo.
17. Shimizu N, Tanabe-Tochikura A, Kuroiwa Y, Takada K: Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV. J Virol 1994, 68:6069-6073.
18. Ruf IK, Rhyne PW, Yang H, Borza CM, Hutt-Fletcher LM, Cleveland JL, Sample JT: Epstein-barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma. Mol Cell Biol 1999, 19:1651-1660. Re-establishment of Latency I in EBV-negative BL cells restores tumorigenicity. This is not achieved by EBNA1 alone.
19. Komano J, Sugiura M, Takada K: Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata. J Virol 1998, 72:9150-9156. Re-establishment of Latency I in EBV-negative BL cells restores tumorigenicity. This is not achieved by EBNA1 alone.
20. Tao Q, Robertson KD, Manns A, Hildesheim A, Ambinder RF: Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue. Blood 1998, 91:1373-1381.
21. Tao Q, Robertson KD, Manns A, Hildesheim A, Ambinder RF: The Epstein-Barr virus major latent promoter Qp is constitutively active, hypomethylated, and methylation sensitive. J Virol 1998, 72:7075-7083. Shows that control of latent gene expression in BL is due to the methylation status of the relevant promoters.
22. Masucci MG, Klein E: Cell phenotype dependent expression of MHC class I antigens in Burkitt's lymphoma cell lines. Semin Cancer Biol 1991, 2:63-71.
23. Khanna R, Cooper L, Kienzle N, Moss DJ, Burrows SR, Khanna KK: Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells. J Immunol 1977, 159:5782-5785. Provides a method for enhancement of antigen presentation and CTL recognition in BL cells.
24. Leblond V, Davi F, Charlotte F, Dorent R, Bitker MO, Sutton L, Gandjbakhch I, Binet JL, Raphael M: Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 1998, 16:2052-2059. Differences between EBV positive and negative cases of PT-LPD are identified.
25. Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA, et al.: Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995, 85:552-565.
26. Chadburn A, Chen JM, Hsu DT, Frizzera G, Cesarman E, Garrett TJ, et al: The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant. Cancer 1998, 82:1978-1987. Differences in clinical behavior of PT-LPDs are found among different morphologic categories.
27. Cesarman E, Chadburn A, Liu YF, Migliazza A, Dalla-Favera R, Knowles DM: BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome. Blood 1998, 92:2294-2302. Provides an objective molecular parameter for prediction of response to reduction in immunosuppression of EBV-positive PT-LPDs.
28. Micallef IN, Chhanabhai M, Gascoyne RD, Shepherd JD, Fung HC, Nantel SH, et al.: Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience. Bone Marrow Transplant 1998, 22:981-987.
29. Hale G, Waldmann H: Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. Blood 1998, 91:3079-3083.
30. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, et al.: Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994, 330:1185-1191.
31. Heslop HE, Brenner MK, Rooney CM: Donor T cells to treat EBV-associated lymphoma [letter]. N Engl J Med 1994, 331:679-680.
32. Orentas RJ, Lemas MV, Mullin MJ, Colombani PM, Schwarz K, Ambinder R: Feasibility of cellular adoptive immunotherapy for Epstein-Barr-virus-associated lymphomas using haploidentical donors. J Hematother 1998, 7:257-261.
33. Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, et al: Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998, 92:1549-1555. EBV-specific T cells from donor lymphocytes were used successfully in the prophylaxis and treatment of PT-LPDs.
34. Wheatley GH, 3rd, McKinnon KP, Iacobucci M, Mahon S, Gelber C, Lyerly HK: Dendritic cells improve the generation of Epstein-Barr virus-specific cytotoxic T lymphocytes for the treatment of posttransplantation lymphoma. Surgery 1998, 124:171-176.
35. Gaidano G, Carbone A, Dalla-Favera R: Genetic basis of acquired immunodeficiency syndrome-related lymphomagenesis. J Natl Cancer Inst Monogr 1998, 23:95-100.
36. Davi F, Delecluse HJ, Guiet P, Gabarre J, Fayon A, Gentilhomme O, et al.: Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin's lymphomas. Burkitt's Lymphoma Study Group. J Clin Oncol 1998, 16:3788-3795.
37. Kersten MJ, Van Gorp J, Pals ST, Boon F, Van Oers MH: Expression of Epstein-Barr virus latent genes and adhesion molecules in AIDS-related non-Hodgkin's lymphomas: correlation with histology and CD4-cell number. Leuk Lymphoma 1998, 30:515-524. Provides a biologic explanation for some clinical differences seen among various categories of AIDS-related lymphomas.
38. Larocca LM, Capello D, Rinelli A, Nori S, Antinori A, Gloghini A, et al.: The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. Blood 1998, 92:1011-1019.
39. Jaffe ES, Krenacs L, Kumar S, Kingma DW, Raffeld M: Extranodal peripheral T-cell and NK-cell neoplasms. Am J Clin Pathol 1999, 111:S46-55.
40. Elenitoba-Johnson KS, Zarate-Osorno A, Meneses A, Krenacs L, Kingma DW, Raffeld M, et al.: Cytotoxic granular protein expression, Epstein-Barr virus strain type, and latent membrane protein-1 oncogene deletions in nasal T-lymphocyte/natural killer cell lymphomas from Mexico. Mod Pathol 1998, 11:754-761.
41. Tsuchiyama J, Yoshino T, Mori M, Kondoh E, Oka T, Akagi T, et al.: Characterization of a novel human natural killer-cell line (NK-YS) established from natural killer cell lymphoma/leukemia associated with Epstein-Barr virus infection. Blood 1998, 92:1374-1383.
42. Kanegane H, Yachie A, Miyawaki T, Tosato G: EBV-NK cells interactions and lymphoproliferative disorders. Leuk Lymphoma 1998, 29:491-498.
43. Ho JW, Ho FC, Chan AC, Liang RH, Srivastava G: Frequent detection of Epstein-Barr virus-infected B cells in peripheral T-cell lymphomas. J Pathol 1998, 185:79-85.
44. Harris NL: The many faces of Hodgkin's disease around the world: what have we learned from its pathology? Ann Oncol 1998, 9:S45-56.
45. Kuppers R, Rajewsky K: The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Annu Rev Immunol 1998, 16:471-493.
46. Murray PG, Constandinou CM, Crocker J, Young LS, Ambinder RF: Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease. Blood 1998, 92:2477-2483. Expression of MHC class I and TAP molecules in HD is identified, suggesting the possibility of immunologic control.
47. Lee SP, Constandinou CM, Thomas WA, Croom-Carter D, Blake NW, Murray PG, et al.: Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on Epstein-Barr virus-specific cytotoxic T-cell recognition. Blood 1998, 92:1020-1030. MHC class I and TAP molecules are found to be expressed of in HD, allowing recognition by CTLs which is not abrogated by IL-10.
48. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994, 266:1865-1869.
49. Boshoff C, Weiss RA: Kaposi's sarcoma-associated herpesvirus: Adv Cancer Res 1998, 75:57-86.
50. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM: Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body cavity-based lymphomas. N Eng J Med 1995, 332:1186-1191.
51. Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Said J, et al.: Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpesvirus. Blood 1996, 88:645-656.
52. Nador RG, Cesarman E, Knowles DM, Said JW: Herpes-like DNA sequences in a body-cavity-based lymphoma in an HIV-negative patient [letter]. N Engl J Med 1995, 333:943.
53. Said JW, Tasaka T, Takeuchi S, Asou H, de Vos S, Cesarman E, et al.: Primary effusion lymphoma in women: Report of two cases of Kaposi's sarcoma-herpes virus-associated effusion-based lymphoma in human immunodeficiency virus-negative women. Blood 1996, 88:3124-3128.
54. Mesri EA, Cesarman E, Arvanitakis L, Rafii S, Moore MAS, Posnett DN, et al.: Human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus is a new transmissible virus that infects B cells. J Exp Med 1996, 183:2385-2390.
55. Flore O, Rafii S, Ely S, O'Leary JJ, Hyjek EM, Cesarman E: Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus. Nature 1998, 394:588-592.
56. Cesarman E, Knowles DM: The role of Kaposi's sarcoma-associated herpesvirus (qKSHV/HHV-8) in lymphoproliferative diseases. Sem Cancer Biol (in press).
57. Gaidano G, Gloghini A, Gattei V, Rossi MF, Cilia AM, Godeas C, et al.: Association of Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma with expression of the CD138/syndecan-1 antigen. Blood 1997, 90:4894-4900. The expression of CD138/syndecan-1 indicates that PEL are at a late stage of B-cell differentiation.
58. Matolcsy A, Nador RG, Cesarman E, Knowles DM: Immunoglobulin VH gene mutational analysis suggests that primary effusion lymphomas derive from different stages of B cell maturation. Am J Pathol 1998, 153:1609-1614. The presence of somatic hypermutation in most PELs suggests that they are of post-germinal center cell origin.
59. Carbone A, Gloghini A, Vaccher E, Zagonel V, Pastore C, Dalla Palma P, et al.: Kaposi's sarcoma-associated herpesvirus DNA sequences in AIDS-related and AIDS-unrelated lymphomatous effusions. Br J Haematol 1996, 94:533-543.
60. Horenstein MG, Nador RG, Chadburn A, Hyjek EM, Inghirami G, Knowles DM, et al.: Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus human herpesvirus-B. Blood 1997, 90:1186-1191.
61. Szekely L, Chen F, Teramoto N, Ehlin-Henriksson B, Pokrovskaja K, Szeles A, et al.: Restricted expression of Epstein-Barr virus (EBV)-encoded, growth transformation-associated antigens in an EBV- and human herpesvirus type 8-carrying body cavity lymphoma line. Gen Virol 1998, 79:1445-1452.
62. Carbone A, Gaidano G, Gloghini A, Larocca LM, Capello D, Canzonieri V, et al.: Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Blood 1998, 91:747-755.
63. Russo JJ, Bohenzky RA, Chien M-C, Chen J, Yan M, Maddalena D, et al.: Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U S A 1996, 93:14862-14867.
64. Gao SJ, Boschoff C, Jayachandra S, Weiss RA, Chang Y, Moore PS: KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway. Oncogene 1997, 15:1979-1985.
65. Zimring JC, Goodbourn S, Offermann MK: Human herpesvirus 8 encodes an interferon regulatory factor (IRF) homolog that represses IRF-1-mediated transcription. J Virol 1998, 72:701-707. Molecular characterization of vIRF shows that it represses IRF-1 mediated transcription.
66. Li M, Lee H, Guo J, Neipel F, Fleckenstein B, Ozato K, Jung JU: Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor. J Virol 1998, 1998:5433-5440. Viral IRF induced transformation of NIH 3T3 cells, inhibited cellular IFN-mediated signal transduction, and had an effect in KSHV gene expression.
67. Arvanitakis L, Geras-Raaka E, Gershengorn MC, Cesarman E: Human herpesvirus KSHV encodes a constitutively active G protein-coupled receptor linked to cell proliferation. Nature 1997, 385:347-350.
68. Bais C, Santomasso B, Coso O, Arvanitakis L, Geras Raaka E, Gutkind JS, et al.: G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and ang iogenesis activator. Nature 1998, 391:86-89. Shows that KSHV GPCR induces transformation, tumorigenesis, and VEGF-mediated angiogenesis, and activates inflammatory signaling cascades.
69. Lee H, Veazey R, Williams K, Li M, Guo J, Neipel F, et al.: Deregulation of cell growth by the K1 gene of Kaposi's sarcoma-associated herpesvirus. Nat Med 1998, 4:435-440. The K1 gene of KSHV is transforming when expressed in rodent fibroblasts and in a simian model of lymphomagenesis using a recombinant herpesvirus. The K1 protein of KSHV contains a functional ITAM motif that can transduce signals to induce cellular activation.
70. Muralidhar S, Pumfery AM, Hassani M, Sadaie MR, Azumi N, Kishishita M, et al.: Identification of kaposin (open reading frame K12) as a human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) transforming gene. J Virol 1998, 72:4980-4988. ORF K12 of KSHV is found to encode a transforming protein when expressed in rodent fibroblasts.
71. Lee H, Guo J, Li M, Choi JK, DeMaria M, Rosenzweig M, et al.: Identification of an immunoreceptor tyrosine-based activation motif of K1 transforming protein of Kaposi's sarcoma-associated herpesvirus. Mol Cell Biol 1998, 18:5219-5228. The K1 protein of KSHV contains a functional ITAM motif that can transduce signals to induce cellular activation.
72. Moore PS, Boschoff C, Weiss RA, Chang Y: Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 1996, 274:1739-1744.
73. Molden J, Chang Y, You Y, Moore PS, Goldsmith MA: A Kaposi's sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. J Biol Chem 1997, 272:19625-19631.
74. Nicholas J, Ruvolo VR, Burns WH, Sandford G, Wan XY, Ciufo D, et al.: Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nature Med 1997, 3:287-292.
75. Godden-Kent D, Talbot SJ, Boshoff C, Chang Y, Moore P, Weiss RA, et al. The cyclin encoded by Kaposi's sarcoma-associated herpesvirus stimulates cdk6 to phosphorylate the retinoblastoma protein and histone H1. J Virol 1997, 71:4193-4198
76. Li M, Lee H, Yoon D-W, Albrecht J-C, Fleckenstein B, Jung J: Kaposi's sarcoma-associated herpesvirus encodes a functional cyclin. J Virol 1997, 71:1984-1991.
77. Ellis M, Chew YP, Fallis L, Freddersdorf S, Boshoff C, Weiss RA, et al.: Degradation of p27(Kip) cdk inhibitor triggered by Kaposi's sarcoma virus cyclin-cdk6 complex. Embo J 1999, 18:644-653. Viral cyclin can induce degradation of the cdk inhibitor p27/Kip1 when complexed with CDK 6.
78. Mann DJ, Child ES, Swanton C, Laman H, Jones N. Modulation of p27Kip1 levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus. EMBO J 1999, 18:654-663. Viral cyclin can induce degradation of the cdk inhibitor p27/Kip1 when complexed with CDK 6.
79. Cheng EHY, Nicholas J, Bellows DS, Hayward GS, Guo HG, Reitz MS, et al.: A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak. Proc Natl Acad Sci U S A 1997, 94:690-694.
80. Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F, et al.: Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997, 386:517-521.
81. Cesarman E, Nador RG, Bar F, Bohenzky RA, Russo JJ, Moore PS, et al.: Kaposi's sarcoma associated herpresvirus contains G. protein-coupled receptor and cyclin D homologs which are expressed in Kaposi's sarcoma and malignant lymphoma. J. Virol 1996, 70:8218-8223.
82. Staskus KA, Zhong W, Gebhard K, Herndier B, Wang H, Renne R, et al.: Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol 1997, 71:715-719.
83. Sarid R, Flore O, Bohenzky RA, Chang Y, Moore PS: Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1). J Virol 1998, 72:1005-1012.
84. Sarid R, Wiezorek JS, Moore PS, Chang Y: Characterization and cell cycle regulation of the major Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent genes and their promoter. J Virol 1999, 73:1438-1446. Provides a good characterization of latent expression of a cluster of genes that includes vFLIP and vCyclin and their regulation by the cell cycle.
85. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC: Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 1980, 77:7415-7419.
86. Watanabe S, Mukai K, Shimoyama M: Adult T cell leukemia/lymphoma. In Neoplastic Hematopathology. Edited by Knowles DM. Baltimore:Williams & Wilkins; 1992:1281-1294.
87. Cann AJ, Chen ISY: Human T-cell leukemia virus types I and II. In Fields Virology, vol 2. Edited by Fields BN, Knipe DM, Howley PM. Philadelphia:Lippincott-Raven; 1996:1849-1880.
88. Dalgleish AG: Human T-cell lymphotropic virus type 1 - infections and pathogenesis. Curr Opin Infect Dis 1998, 11:195-199.
89. Reitz MS, Jr, Popovic M, Haynes BF, Clark SC, Gallo RC: Relatedness by nucleic acid hybridization of new isolates of human T-cell leukemia-lymphoma virus (HTLV) and demonstration of provirus in uncultured leukemic blood cells. Virology 1983, 126:688-672.
90. Yoshida M, Hattori S, Seiki M: Molecular biology of human T-cell leukemia virus associated with adult T-cell leukemia. Curr Top Microbiol Immunol 1985, 115:157-175.
91. Yoshida M, Seiki M, Yamaguchi K, Takatsuki K: Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci U S A 1984, 81:2534-2537.
92. Cesarman E, Chadburn A, Inghirami G, Gaidano G, Knowles DM: Structural and functional analysis of oncogenes and tumor suppressor genes in adult T-cell leukemia/lymphoma shows frequent p53 mutations. Blood 1992, 80:3205-3216.
93. Pise-Masison CA, Radonovich M, Sakaguchi K, Appella E, Brady JN: Phosphorylation of p53: a novel pathway for p53 inactivation in human T-cell lymphotropic virus type 1-transformed cells. J Virol 1998, 72:6348-6355.
94. Uchida T, Kinoshita T, Murate T, Saito H, Hotta T: CDKN2 (MTS1/p16INK4A) gene alterations in adult T-cell leukemia/lymphoma. Leuk Lymphoma 1998, 29:27-35. Review of the high prevalence of loss of p16INK4 tumor suppressor gene in ATLL.
95. Maruyama K, Fukushima T, Kawamura K, Mochizuki S: Chromosome and gene rearrangements in immortalized human lymphocytes infected with human T-lymphotropic virus type I. Cancer Res 1990, 50 (suppl):5697-5702.
96. Fukuhara S, Hinuma Y, Gotoh YI, Uchino H: Chromosome aberrations in T lymphocytes carrying adult T-cell leukemia-associated antigens (ATLA) from healthy adults. Blood 1983, 61:205-207.
97. Sanada I, Tanaka R, Kumagai E, Tsuda H, Nishimura H, Yamaguchi K, et al.: Chromosomal aberrations in adult T cell leukemia: relationship to the clinical severity. Blood 1985, 65:649-654.
98. Felber BK, Paskalis H, Kleinman-Ewing C, Wong-Staal F, Pavlakis GN: The pX protein of HTLV-I is a transcriptional activator of its long terminal repeats. Science 1985, 229:675-679.
99. Hiscott J, Petropoulos L, Lacoste J: Molecular interactions between HTLV-1 Tax protein and the NF-kappa B/kappa B transcription complex. Virology 1995, 214:3-11.
100. Flint J, Shenk T: Viral transactivating proteins. Annual Review of Genetics 1997, 31:177-212.
101. Grassmann R, Dengler C, Muller-Fleckenstein I, Fleckenstein B, McGuire K, Dokhelar MC, et al.: Transformation to continuous growth of primary human T lymphocytes by human T-cell leukemia virus type 1 X-region genes transduced by a Herpesvirus saimiri vector. Proc Natl Acad Sci U S A 1989, 86:3351-3355.
102. Grassmann R, Berchtold S, Radant I, Alt M, Fleckenstein B, Sodroski JG, et al.: Role of human T-cell leukemia virus type 1 X region proteins in immortalization of primary human lymphocytes in culture. J Virol 1992, 66:4570-4575.
103. Hinrichs SH, Nerenberg M, Reynolds RK, Khoury G, Jay G: A transgenic mouse model for human neurofibromatosis. Science 1987, 237:1340-1343.
104. Nerenberg M, Hinrichs SH, Reynolds RK, Khoury G, Jay G: The tat gene of human T-lymphotropic virus type 1 induces mesenchymal tumors in transgenic mice. Science 1987, 237:1324-1329.
105. Grossman WJ, Kimata JT, Wong FH, Zutter M, Ley TJ, Ratner L: Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. Proc Natl Acad Sci U S A 1995, 92:1057-1061.
106. Lenzmeier BA, Giebler HA, Nyborg JK: Human T-cell leukemia virus type 1 Tax requires direct access to DNA for recruitment of CREB binding protein to the viral promoter. Mol Cell Biol 1998, 18:721-731.
107. Leung K, Nabel GJ: HTLV-1 transactivator induces interleukin-2 receptor expression through an NF-kappa B-like factor. Nature 1988, 333:776-778.
108. Ruben S, Poteat H, Tan TH, Kawakami K, Roeder R, Haseltine W, et al.: Cellular transcription factors and regulation of IL-2 receptor gene expression by HTLV-1 tax gene product. Science 1988, 241:89-92.
109. Petropoulos L, Hiscott J: Association between HTLV-1 Tax and I kappa B alpha is dependent on the I kappa B alpha phosphorylation state. Virology 1998, 252:189-199.
110. Nicot C, Tie F, Giam CZ: Cytoplasmic forms of human T-cell leukemia virus type 1 Tax induce NF-κB activation. J Virol 1998, 72:6777-6784.
111. Geleziunas R, Ferrell S, Lin X, Mu Y, Cunningham ET, Jr., Grant M, et al: Human T-cell leukemia virus type 1 Tax induction of NF-kappaB involves activation of the IkappaB kinase alpha (IKKalpha) and IKKbeta cellular kinases. Mol Cell Biol 1998, 18:5157-5165. These two papers show how Tax activates cytoplasmic signaling pathways leading to NF-κB activation. These two papers show how Tax activates cytoplasmic signaling pathways leading to NF-κB activation.
112. Iwanaga Y, Tsukahara T, Ohashi T, Tanaka Y, Arai M, Nakamura M, et al: Human T-cell leukemia virus type 1 tax protein abrogates interleukin-2 dependence in a mouse T-cell line. J Virol 1999, 73:1271-1277. Demonstrates that Tax expression can lead to IL-2 independence in an IL-2 dependent cell line.
113. Migone TS, Cacalano NA, Taylor N, Yi T, Waldmann TA, Johnston JA: Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T-lymphotropic virus type I-transformed T cells. Proc Natl Acad Sci U S A 1998, 95:3845-3850. Shows the importance of the disregulation of the IL-2 signaling pathway in HTLV-1 mediated transformation.
114. Yin MJ, Paulssen E, Seeler J, Gaynor RB: Chimeric proteins composed of Jun and CREB define domains required for interaction with the human T-cell leukemia virus type 1 Tax protein. J Virol 1995, 69:6209-6218.
115. Bantignies F, Rousset R, Desbois C, Jalinot P: Genetic characterization of transactivation of the human T-cell leukemia virus type 1 promoter: Binding of Tax to Tax-responsive element 1 is mediated by the cyclic AMP-responsive members of the CREB/ATF family of transcription factors. Mol Cell Biol 1996, 16:2174-2182.
116. Gachon F, Peleraux A, Thebault S, Dick J, Lemasson I, Devaux C, Mesnard JM: CREB-2, a cellular CRE-dependent transcription repressor, functions in association with Tax as an activator of the human T-cell leukemia virus type 1 promoter. J Virol 1998, 72:8332-8337.
117. Kwok RP, Laurance ME, Lundblad JR, Goldman PS, Shih H, Connor LM, et al.: Control of cAMP-regulated enhancers by the viral transactivator Tax through CREB and the co-activator CBP. Nature 1996, 380:642-646.
118. Harrod R, Tang Y, Nicot C, Lu HS, Vassilev A, Nakatani Y, et al.: An exposed KID-like domain in human T-cell lymphotropic virus type 1 Tax is responsible for the recruitment of coactivators CBP/p300. Mol Cell Biol 1998, 18:5052-5061.
119. Rosin O, Koch C, Schmitt I, Semmes OJ, Jeang KT, Grassrnann R: A human T-cell leukemia virus Tax variant incapable of activating NF-κB retains its immortalizing potential for primary T-lymphocytes. J Biol Chem 1998, 273:6698-6703. Highlights the Importance of the CREB/ATF-1 transactivating activity of Tax in T-cell transformation.
120. Neuveut C, Low KG, Maldarelli F, Schmitt I, Majone F, Grassmann R, et al: Human T-cell leukemia virus type 1 tax and cell cycle progression-role of cyclin d-cdk and p110rb. Mol Cell Biol 1998, 18:3620-3632. Demonstrates the ability of Tax to activate cyclin/CDK and induce cell cycle entry in T cells in the absence of serum.
121. Schmitt I, Rosin O, Rohwer P, Gossen M, Grassmann R: Stimulation of cyclin-dependent kinase activity and G1- to S-phase transition in human lymphocytes by the human T-cell leukemia/lymphotropic virus type 1 Tax protein. J Virol 1998, 72:633-640. Shows that Tax induces CDK4 and CDK6 in primary T-cell lymphocytes to induce cell proliferation.
122. Mulloy JC, Kislyakova T, Cereseto A, Casareto L, LoMonico A, Fullen J, et al.: Human T-cell lymphotropic/leukemia virus type 1 Tax abrogates p53-induced cell cycle arrest and apoptosis through its CREB/ATF functional domain. J Virol 1998, 72:8852-8860. Shows that the CREB/ATF binding activity of Tax allows it to suppress p53 transcriptional activity and p53-induced cell arrest and apoptosis.
123. Pise-Masison CA, Choi KS, Radonovich M, Dittmer J, Kim SJ, Brady JN: Inhibition of p53 transactivation function by the human T-cell lymphotropic virus type 1 Tax protein. J Virol 1998, 72:1165-1170.
124. Miyake H, Suzuki T, Hirai H, Yoshida M: Trans-activator Tax of human T-cell leukemia virus type 1 enhances mutation frequency of the cellular genome: a Virology 1999, 253:155-161. Demonstrates that Tax can cause genomic instability, increasing the likelihood of cells to acquire oncogenic mutations.